{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T11:43:10Z","timestamp":1794829390950,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["CL-2018-17-002"],"award-info":[{"award-number":["CL-2018-17-002"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"crossref","award":["SGL023\\1023"],"award-info":[{"award-number":["SGL023\\1023"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>X-linked sideroblastic anaemia (XLSA) is commonly due to mutations in the <jats:italic>ALAS2<\/jats:italic> gene and predominantly affects hemizygous males. Heterozygous female carriers of the <jats:italic>ALAS2<\/jats:italic> gene mutation are often asymptomatic or only mildly anaemic. XLSA is usually characterized by microcytic erythrocytes (reduced mean corpuscular volume (MCV)) and hypochromia, along with increased red cell distribution width. However, in females with XLSA the characteristic laboratory findings can be dimorphic and present with macrocytic (elevated MCV) in addition to microcytic red cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of fetal anaemia, presenting in the early third trimester of pregnancy, in a female fetus. Ultrasound findings at 29\u00a0weeks were of cardiomegaly, prominent umbilical veins, a small rim of ascites, and mean cerebral artery peak systolic velocity (PSV) value above 1.5 Multiples of the Median (MoM). She underwent non-invasive prenatal testing that determined the rhesus genotype of the fetus to be rhesus B negative. No red blood cell antibodies were reported. Other investigations to determine the underlying cause of fetal anaemia included microarray comparative genomic hybridization, serology to exclude congenital infection and a peripheral blood film and fetal bilirubin to detect haemolysis. The maternal grandmother had a history of sideroblastic anaemia diagnosed at the age of 17\u00a0years. The mother had mild macrocytic anaemia with haemoglobin of 10.4\u00a0g\/dl and MCV of 104\u00a0fl. The fetal anaemia was successfully treated with two\u00a0in utero\u00a0transfusions\u00a0(IUTs), and delivery occurred via caesarean section at 37\u00a0weeks of gestation. The red cell gene sequencing in both the mother and fetus were heterozygous for an\u00a0<jats:italic>ALAS2<\/jats:italic>\u00a0mutation causing in utero manifestations of XLSA. The haemoglobin on discharge to the local hospital at five days of age was 19.1\u00a0g\/dl. Subsequently, the infant became anaemic, requiring regular 3\u20134 monthly blood transfusions and demonstrating overall normal development. Her anaemia was unresponsive to pyridoxine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is one of four cases reporting multiple female members presenting with discordant clinical features of XLSA from being entirely asymptomatic to hydropic in utero. Our report is novel in that there are no previous cases in the literature of anaemia in a female fetus heterozygous for\u00a0<jats:italic>ALAS2<\/jats:italic>\u00a0mutation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-021-01146-z","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T10:03:12Z","timestamp":1639994592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["X-linked sideroblastic anaemia in a female fetus: a case report and a literature review"],"prefix":"10.1186","volume":"14","author":[{"given":"Diane","family":"Nzelu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2750-8405","authenticated-orcid":false,"given":"Panicos","family":"Shangaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Story","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinthika","family":"Piyasena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi","family":"Alamelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Elmakky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pelidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Mayhew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srividhya","family":"Sankaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"1146_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.freeradbiomed.2018.08.008","volume":"133","author":"T Fujiwara","year":"2019","unstructured":"Fujiwara T, Harigae H. Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia. Free Radic Biol Med. 2019;133:179\u201385. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.08.008.","journal-title":"Free Radic Biol Med"},{"key":"1146_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/pbc.22244","volume":"54","author":"AK Bergmann","year":"2010","unstructured":"Bergmann AK, Campagna DR, McLoughlin EM, Agarwal S, Fleming MD, Bottomley SS, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010;54:273\u20138. https:\/\/doi.org\/10.1002\/pbc.22244.","journal-title":"Pediatr Blood Cancer"},{"key":"1146_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1053\/j.seminhematol.2009.07.001","volume":"46","author":"C Camaschella","year":"2009","unstructured":"Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol. 2009;46:371\u20137. https:\/\/doi.org\/10.1053\/j.seminhematol.2009.07.001.","journal-title":"Semin Hematol"},{"key":"1146_CR4","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/ijlh.12902","volume":"41","author":"M-I Moreno-Carralero","year":"2019","unstructured":"Moreno-Carralero M-I, Arrizabalaga-Amuchastegui B, S\u00e1nchez-Calero-Guilarte J, Morado-Arias M, Velasco-Valdazo A-E, De-la-Iglesia-I\u00f1igo S, et al. Missense variants in ALAS2 gene in five patients. Int J Lab Hematol. 2019;41:e5-9. https:\/\/doi.org\/10.1111\/ijlh.12902.","journal-title":"Int J Lab Hematol"},{"key":"1146_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bcmd.2017.07.003","volume":"66","author":"M-A Le Rouzic","year":"2017","unstructured":"Le Rouzic M-A, Fouquet C, Leblanc T, Touati M, Fouyssac F, Vermylen C, et al. Non syndromic childhood onset congenital sideroblastic anemia: a report of 13 patients identified with an ALAS2 or SLC25A38 mutation. Blood Cells Mol Dis. 2017;66:11\u20138. https:\/\/doi.org\/10.1016\/j.bcmd.2017.07.003.","journal-title":"Blood Cells Mol Dis"},{"key":"1146_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12185-016-1949-7","volume":"103","author":"T Katsurada","year":"2016","unstructured":"Katsurada T, Kawabata H, Kawabata D, Kawahara M, Nakabo Y, Takaori-Kondo A, et al. A Japanese family with X-linked sideroblastic anemia affecting females and manifesting as macrocytic anemia. Int J Hematol. 2016;103:713\u20137. https:\/\/doi.org\/10.1007\/s12185-016-1949-7.","journal-title":"Int J Hematol"},{"key":"1146_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bcmd.2006.04.003","volume":"37","author":"M Aivado","year":"2006","unstructured":"Aivado M, Gattermann N, Rong A, Giagounidis AAN, Prall WC, Czibere A, et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis. 2006;37:40\u20135. https:\/\/doi.org\/10.1016\/j.bcmd.2006.04.003.","journal-title":"Blood Cells Mol Dis"},{"key":"1146_CR8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/bjh.14164","volume":"178","author":"C Rose","year":"2017","unstructured":"Rose C, Callebaut I, Pascal L, Oudin C, Fournier M, Gouya L, et al. Lethal ALAS2 mutation in males X-linked sideroblastic anaemia. Br J Haematol. 2017;178:648\u201351. https:\/\/doi.org\/10.1111\/bjh.14164.","journal-title":"Br J Haematol"},{"key":"1146_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1172\/JCI78619","volume":"125","author":"VG Sankaran","year":"2015","unstructured":"Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, et al. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. J Clin Invest. 2015;125:1665\u20139. https:\/\/doi.org\/10.1172\/JCI78619.","journal-title":"J Clin Invest"},{"key":"1146_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s12185-014-1723-7","volume":"101","author":"N Roll\u00f3n","year":"2015","unstructured":"Roll\u00f3n N, Fern\u00e1ndez-Jim\u00e9nez MC, Moreno-Carralero MI, Murga-Fern\u00e1ndez MJ, Mor\u00e1n-Jim\u00e9nez MJ. Microcytic anemia in a pregnant woman: beyond iron deficiency. Int J Hematol. 2015;101:514\u20139. https:\/\/doi.org\/10.1007\/s12185-014-1723-7.","journal-title":"Int J Hematol"},{"key":"1146_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood-2013-10-529933","volume":"123","author":"L Gar\u00e7on","year":"2014","unstructured":"Gar\u00e7on L, Kannengiesser C. A double red cells population in a woman with a microcytic anemia. Blood. 2014;123:808. https:\/\/doi.org\/10.1182\/blood-2013-10-529933.","journal-title":"Blood"},{"key":"1146_CR12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00277-017-3106-7","volume":"96","author":"T Fujiwara","year":"2017","unstructured":"Fujiwara T, Fukuhara N, Ichikawa S, Kobayashi M, Okitsu Y, Onishi Y, et al. A novel heterozygous ALAS2 mutation in a female with macrocytic sideroblastic anemia resembling myelodysplastic syndrome with ring sideroblasts: a case report and literature review. Ann Hematol. 2017;96:1955\u20137. https:\/\/doi.org\/10.1007\/s00277-017-3106-7.","journal-title":"Ann Hematol"},{"key":"1146_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bcmd.2005.12.004","volume":"36","author":"PL Lee","year":"2007","unstructured":"Lee PL, Barton JC, Rao SV, Acton RT, Adler BK, Beutler E. Three kinships with ALAS2 P520L (c. 1559 C \u2013> T) mutation, two in association with severe iron overload, and one with sideroblastic anemia and severe iron overload. Blood Cells Mol Dis. 2007;36:292\u20137. https:\/\/doi.org\/10.1016\/j.bcmd.2005.12.004.","journal-title":"Blood Cells Mol Dis"},{"key":"1146_CR14","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1182\/blood.V96.13.4363","volume":"96","author":"M Cazzola","year":"2000","unstructured":"Cazzola M, May A, Bergamaschi G, Cerani P, Rosti V, Bishop DF. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood. 2000;96:4363\u20135. https:\/\/doi.org\/10.1182\/blood.V96.13.4363.","journal-title":"Blood"},{"key":"1146_CR15","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1172\/JCI118258","volume":"96","author":"PD Cotter","year":"1995","unstructured":"Cotter PD, May A, Fitzsimons EJ, Houston T, Woodcock BE, Al-Sabah AI, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest. 1995;96:2090\u20136. https:\/\/doi.org\/10.1172\/JCI118258.","journal-title":"J Clin Invest"},{"key":"1146_CR16","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/humu.21455","volume":"32","author":"S Ducamp","year":"2011","unstructured":"Ducamp S, Kannengiesser C, Touati M, Gar\u00e7on L, Guerci-Bresler A, Guichard JF, et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat. 2011;32:590\u20137. https:\/\/doi.org\/10.1002\/humu.21455.","journal-title":"Hum Mutat"},{"key":"1146_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/JBM.S232644","volume":"11","author":"G Abu-Zeinah","year":"2020","unstructured":"Abu-Zeinah G, DeSancho MT. Understanding sideroblastic anemia: an overview of genetics, epidemiology, pathophysiology and current therapeutic options. J Blood Med. 2020;11:305\u201318. https:\/\/doi.org\/10.2147\/JBM.S232644.","journal-title":"J Blood Med"},{"key":"1146_CR18","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1038\/s41586-021-03758-y","volume":"597","author":"S Gudmundsson","year":"2021","unstructured":"Gudmundsson S, Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, et al. Addendum: the mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2021;597:E3-4. https:\/\/doi.org\/10.1038\/s41586-021-03758-y.","journal-title":"Nature"},{"key":"1146_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201323. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"1146_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00439-011-0994-9","volume":"130","author":"C Yang","year":"2011","unstructured":"Yang C, Chapman AG, Kelsey AD, Minks J, Cotton AM, Brown CJ. X-chromosome inactivation: molecular mechanisms from the human perspective. Hum Genet. 2011;130:175\u201385. https:\/\/doi.org\/10.1007\/s00439-011-0994-9.","journal-title":"Hum Genet"},{"key":"1146_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jmoldx.2011.05.003","volume":"13","author":"B Bertelsen","year":"2011","unstructured":"Bertelsen B, T\u00fcmer Z, Ravn K. Three new loci for determining X chromosome inactivation patterns. J Mol Diagnostics. 2011;13:537\u201340. https:\/\/doi.org\/10.1016\/j.jmoldx.2011.05.003.","journal-title":"J Mol Diagnostics"},{"key":"1146_CR22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1651-2227.1992.tb12324.x","volume":"81","author":"K Andersen","year":"1992","unstructured":"Andersen K, Kaad P. Congenital sideroblastic anaemia with intrauterine symptoms and early lethal outcome. Acta Paediatr. 1992;81:652\u20133. https:\/\/doi.org\/10.1111\/j.1651-2227.1992.tb12324.x.","journal-title":"Acta Paediatr"},{"key":"1146_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood.V88.1.59.bloodjournal88159","volume":"88","author":"L Busque","year":"1996","unstructured":"Busque L, Mio R, Mattioli J, Brais E, Blais N, Lalonde Y, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood. 1996;88:59\u201365. https:\/\/doi.org\/10.1182\/blood.V88.1.59.bloodjournal88159.","journal-title":"Blood"},{"key":"1146_CR24","first-page":"1101","volume":"58","author":"JW Belmont","year":"1996","unstructured":"Belmont JW. Genetic control of X inactivation and processes leading to X-inactivation skewing. Am J Hum Genet. 1996;58:1101\u20138.","journal-title":"Am J Hum Genet"},{"key":"1146_CR25","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1093\/nar\/25.13.2661","volume":"25","author":"B Hendrich","year":"1997","unstructured":"Hendrich B. Identification and characterization of the human XIST gene promoter: implications for models of X chromosome inactivation. Nucleic Acids Res. 1997;25:2661\u201371. https:\/\/doi.org\/10.1093\/nar\/25.13.2661.","journal-title":"Nucleic Acids Res"},{"key":"1146_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.21037\/atm.2019.09.163","volume":"7","author":"J Xue","year":"2019","unstructured":"Xue J, He Q, Xie X, Su A, Cao S. Clinical utility of targeted gene enrichment and sequencing technique in the diagnosis of adult hereditary spherocytosis. Ann Transl Med. 2019;7:527\u2013527. https:\/\/doi.org\/10.21037\/atm.2019.09.163.","journal-title":"Ann Transl Med"},{"issue":"Suppl","key":"1146_CR27","first-page":"A352","volume":"63","author":"SS Bottomley","year":"1998","unstructured":"Bottomley SS, Wise PD, Wasson EG. X-linked sideroblastic anemia in ten female probands due to ALAS2 mutations and skewed X chromosome inactivation. Am J Hum Genet. 1998;63(Suppl):A352.","journal-title":"Am J Hum Genet"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01146-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-021-01146-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01146-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T10:12:25Z","timestamp":1639995145000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-021-01146-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1186\/s12920-021-01146-z","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"1 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent to participate was obtained from the\u00a0patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written informed consent for publication of identifying images or other personal or clinical details was obtained from all of the participants and from the parents or legal guardians of any participant under the age of 18.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}